Search Within

Matthew G Fury

Formats
  1. Journal Article (57)
  2. Meeting Abstract (42)
  3. Book Section (2)
  4. Book Whole (1)
Groups
  1. Department of Medicine (93)
  2. Solid Tumor Oncology Division (93)
  3. Head and Neck Service (81)
  4. Radiology, Department of (53)
  5. Surgery (46)
  6. Radiation Oncology, Department of (41)

More Groups

People
  1. David Pfister (69)
  2. Eric Sherman (52)
  3. Nancy Lee (41)
  4. Sofia Haque (29)
  5. Alan Ho (26)
  6. Nora Katabi (20)

More People

Years
  1. 2022 (1)
  2. 2020 (1)
  3. 2019 (2)
  4. 2018 (1)
  5. 2017 (5)
  6. 2016 (3)

More Years

Publications
  1. Journal of Clinical Oncology (34)
  2. International Journal of Radiation Oncology, Biology, Physics (19)
  3. Cancer Chemotherapy and Pharmacology (6)
  4. Cancer (5)
  5. Annals of Oncology (3)
  6. Head & Neck (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (34)
  2. Elsevier Inc. (29)
  3. Springer (10)
  4. Wiley Blackwell (6)
  5. Harborside Press (3)
  6. John Wiley & Sons, Inc. (3)

More Publishers

Results (102)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus–related malignancies
    Journal Article

    Burman, B.; Drutman, S. B.; Fury, M. G.; Wong, R. J.; Katabi, N.; Ho, A. L.; Pfister, D. G.
    Oral Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1b study of cetuximab and BYL719 (alpelisib) concurrent with intensity modulated radiation therapy in stage III-IVB head and neck squamous cell carcinoma
    Journal Article

    Dunn, L. A.; Riaz, N.; Fury, M. G.; McBride, S. M.; Michel, L.; Lee, N. Y.; Sherman, E. J.; Baxi, S. S.; Haque, S. S.; Katabi, N.; more...
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save
  • MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
    Journal Article

    Novoplansky, O.; Fury, M.; Prasad, M.; Yegodayev, K.; Zorea, J.; Cohen, L.; Pelossof, R.; Cohen, L.; Katabi, N.; Cecchi, F.; more...
    International Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: Results from a phase I/II expansion cohort
    Journal Article

    Segal, N. H.; Ou, S. H. I.; Balmanoukian, A.; Fury, M. G.; Massarelli, E.; Brahmer, J. R.; Weiss, J.; Schöffski, P.; Antonia, S. J.; Massard, C.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer
    Journal Article

    Dunn, L. A.; Fury, M. G.; Sherman, E. J.; Ho, A. A.; Katabi, N.; Haque, S. S.; Pfister, D. G.
    Head & Neck (2018)

    Fulltext@MSK | Save
  • Phase Ib study of cetuximab + BYL719 + IMRT in stage III-IVB head and neck squamous cell carcinoma (HNSCC)
    Meeting Abstract

    Dunn, L.; Riaz, N.; Baxi, S. S.; McBride, S. M.; Sherman, E. J.; Michel, L.; Haque, S.; Katabi, N.; Wong, R. J.; Xiao, H.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save
  • A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Journal Article

    Dunn, L. A.; Fury, M. G.; Xiao, H.; Baxi, S. S.; Sherman, E. J.; Korte, S.; Pfister, C.; Haque, S.; Katabi, N.; Ho, A. L.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer
    Journal Article

    Sherman, E. J.; Dunn, L. A.; Ho, A. L.; Baxi, S. S.; Ghossein, R. A.; Fury, M. G.; Haque, S.; Sima, C. S.; Cullen, G.; Fagin, J. A.; more...
    Cancer (2017)

    Fulltext@MSK | Save
  • The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma
    Journal Article

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Straus, D. J.; Moskowitz, A. J.; Younes, A.; Matasar, M. J.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save